宜明昂科生物医药技术(上海)有限公司
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, HKEX-listed immuno-oncology company developing bispecific antibodies and fusion proteins that engage both innate and adaptive immune systems to treat hematological malignancies, solid tumors, and autoimmune diseases.
- Company typePublic
- Founded2015
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What 宜明昂科生物医药技术(上海)有限公司 does
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage biopharmaceutical company founded in June 2015 by Dr. Tian Wenzhi and headquartered in Shanghai, China, with a Hong Kong Stock Exchange listing (01541.HK) since September 2023. The company develops immuno-oncology biologics that systematically engage both the innate and adaptive immune systems, with a pipeline of 10+ in-house originated assets targeting hematological malignancies, solid tumors, and autoimmune diseases. Core technology includes the proprietary mAb-Trap bispecific antibody platform (yielding CD47×CD20, CD47×HER2, VEGF×PD-L1, and CD47×PD-L1 candidates), the SIRPα-Fc fusion protein design (timdarpacept/IMM01, the first such molecule to enter clinical development in China), and a recombinant human hyaluronidase (rHuPH20) platform enabling subcutaneous delivery of macromolecular drugs.
Lead assets timdarpacept (IMM01) and amulirafusp alfa (IMM0306) are in Phase III for chronic myelomonocytic leukemia (CMML) and relapsed/refractory follicular lymphoma respectively, while palverafusp alfa (IMM2510) is in Phase III for squamous NSCLC with global rights (ex-Greater China) licensed to Instil Bio/Axion Bio in a deal valued at over US$2 billion. The pipeline also includes tazlestobart (IMM27M, CTLA-4), IMM2902 (CD47×HER2, FDA Fast Track), IMM2520, IMM47, IMM40H, and IMM72 (pulmonary arterial hypertension).
The company is pre-revenue with no commercial product sales. Revenue mechanics consist of upfront payments, development/registration/commercial milestones, and single-digit to low double-digit royalties under licensing agreements, plus future direct sales upon regulatory approval. Manufacturing is conducted through wholly-owned subsidiary ImmuneOnco BioPharm (Shanghai) Co., Ltd., established in September 2021 in Zhangjiang Science City, while global commercialization outside Greater China is structured through licensing partners (primarily Instil Bio) and an in-house US-based business development function led by the Chief Business Officer.
宜明昂科生物医药技术(上海)有限公司 firmographics
Firmographics- Name
- 宜明昂科生物医药技术(上海)有限公司
- Legal name
- ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
- Website
- https://cn.immuneonco.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, HKEX-listed immuno-oncology company developing bispecific antibodies and fusion proteins that engage both innate and adaptive immune systems to treat hematological malignancies, solid tumors, and autoimmune diseases.
- Ownership category
- akta.pro rank
宜明昂科生物医药技术(上海)有限公司 industry classification
Industry- Product category
- Immuno-Oncology Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industries
- Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
Keywords
Where 宜明昂科生物医药技术(上海)有限公司 is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices5 records
Markets served
宜明昂科生物医药技术(上海)有限公司 business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Licensing and Milestone Payments: ImmuneOnco receives upfront payments, development/registration/commercial milestone payments, and single-digit to low double-digit sales royalties under licensing agreements. Example: Instil Bio/Axion Bio deal worth over $2 billion for IMM2510 and IMM27M outside Greater China.
- Pharmaceutical Product Sales (Future): Pre-revenue clinical-stage company. Revenue expected from global commercialization of its pipeline of immuno-oncology biologics upon regulatory approvals.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
宜明昂科生物医药技术(上海)有限公司 product offering
Product offeringCore offering
ImmuneOnco is a clinical-stage biopharmaceutical company developing immuno-oncology biologics, including bispecific antibodies built on its proprietary mAb-Trap platform, SIRPα-Fc fusion proteins, and recombinant protein therapeutics. Its pipeline of 10+ in-house originated drug candidates targets both innate and adaptive immune pathways for hematologic malignancies (e.g., CMML, follicular lymphoma), solid tumors (e.g., NSCLC, TNBC, HER2-positive cancers), and autoimmune diseases (e.g., SLE, IgG4-RD). The company currently monetizes selected assets (IMM2510 and IMM27M) through an ex-Greater China licensing deal with Instil Bio/Axion Bio valued at over US$2 billion and is building toward direct commercialization upon regulatory approvals.
Product overview
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage, science-driven biotechnology company dedicated to developing immuno-oncology therapies. The company has built a diversified pipeline of 10+ in-house developed assets including drug candidates and proprietary technology platforms. Key products include: Timdarpacept (IMM01), a first-in-China SIRPα-Fc fusion protein targeting CD47 in Phase III for CMML; Amulirafusp Alfa (IMM0306), a CD47×CD20 bispecific antibody in Phase III for follicular lymphoma and expanding into autoimmune diseases; Palverafusp Alfa (IMM2510), a VEGF×PD-L1 bispecific antibody in Phase III for NSCLC with global rights licensed to Instil Bio; Tazlestobart (IMM27M), an ADCC-enhanced CTLA-4 antibody in Phase II for breast cancer; and IMM2902, a CD47×HER2 bispecific in Phase I. The company operates proprietary mAb-Trap and hyaluronidase technology platforms enabling bispecific antibody development and subcutaneous drug delivery respectively.
Differentiator
Problem solved
Functional benefit
Products and services
- Timdarpacept (IMM01) First SIRPα-Fc fusion protein targeting CD47 developed in China. Designed with IgG1 Fc to fully activate macrophages via dual mechanism: blocking the 'don't eat me' signal through CD47/SIRPα disruption and delivering an 'eat me' signal via Fcγ receptor engagement on macrophages. Engineered to avoid binding human red blood cells (avoiding the antigen sink effect), with approximately half the molecular weight of regular IgG providing better tissue permeability. In Phase III for CMML and classic Hodgkin lymphoma.
- Amulirafusp Alfa (IMM0306) CD47×CD20 bispecific antibody developed on the mAb-Trap platform. Does not bind human erythrocytes and has higher affinity for CD20 than rituximab, with stronger ADCC/ADCP activity. In Phase III for relapsed/refractory follicular lymphoma, Phase II/III for IgG4-RD, and Phase II for SLE, lupus nephritis, and membranous nephropathy.
- Palverafusp Alfa (IMM2510) VEGF×PD-L1 bispecific antibody with mAb-Trap structure. Inhibits angiogenesis and sensitizes tumor cells to immune response while activating T cells, NK cells, and macrophages via PD-1/PD-L1 blockade and ADCC/ADCP induction. Differentiated by VEGF trap binding multiple VEGF receptor ligands beyond VEGF-A. In Phase III for squamous NSCLC and Phase II for first-line NSCLC in combination with chemotherapy. Licensed to Instil Bio outside Greater China.
- Tazlestobart (IMM27M) Next-generation CTLA-4 antibody with enhanced ADCC activity. Genetically engineered to induce potent immune responses targeting CTLA-4 overexpressed immune-suppressive Treg cells and promote Treg depletion from the tumor microenvironment. In Phase II for ER+ breast cancer and Phase Ib/II with osimertinib for EGFR-mutated NSCLC. Licensed to Instil Bio outside Greater China.
- IMM2902
Quantifiable outcome
- Phase III CMML trial (IMM01): 173 patients enrolled, 2 months ahead of original timeline
- +4 more outcomes
Companies that use 宜明昂科生物医药技术(上海)有限公司
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
宜明昂科生物医药技术(上海)有限公司 technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
宜明昂科生物医药技术(上海)有限公司 partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Instil Bio / Axion BioflagshipGlobal registrational strategy for IMM2510/SYN-2510 (PD-L1xVEGF bispecific antibody) in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Joint global Phase 3 trials planned. ImmuneOnco leads China development; Instil leads US development.
- Instil Bio / Axion Bio (formerly SynBioTx)flagshipLicense and collaboration agreement worth over $2 billion for IMM2510 and IMM27M. ImmuneOnco retains commercial rights in Greater China and receives upfront payment, development milestones, and single-digit to low double-digit sales royalties outside Greater China. Received aggregate of $50 million upfront and milestone payments as of August 2025, with over $2 billion in potential remaining milestone and royalty payments.
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (stock code: SHA: 688336)coreClinical trial collaboration for IMM01 (CD47 SIRPα-Fc fusion protein) combined with Inetetamab (Cipterbin) in HER2-positive solid tumors. Collaboration mainly conducted by Sunshine Guojian.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
宜明昂科生物医药技术(上海)有限公司 competitors and assessment
Company assessmentDirect peers
- Junshi Biosciences: China-based PD-1-focused biotech (toripalimab) actively expanding into bispecific antibodies and combination oncology regimens; comparable in therapeutic area (immuno-oncology), China commercialization focus, and HKEX-listed status.
- I-Mab Biopharma: Clinical-stage China-US biotech focused on immuno-oncology biologics including bispecific antibodies; directly comparable as a clinical-stage Chinese biotech developing oncology biologics targeting similar mechanisms and indications.
- Keymed Biosciences: Clinical-stage Chinese biotech developing bispecific antibodies and immunology therapeutics with similar pipeline depth and HKEX-listed profile; overlapping CD20/CD47/oncology therapeutic focus makes it a comparable peer.
- CStone Pharmaceuticals: China-based immuno-oncology biotech developing PD-1, PD-L1, and bispecific antibodies for hematologic and solid tumors; comparable in clinical-stage profile, oncology focus, and Greater China commercialization strategy.
- Innovent Biologics: China-based biopharmaceutical company developing monoclonal and bispecific antibodies in oncology (including PD-1, PD-L1, CD47-related targets); directly comparable to ImmuneOnco in pipeline modality, China commercial market focus, and HKEX-listed status.
- Akeso, Inc. Chinese clinical-stage biotech developing bispecific antibodies including ivonescimab (PD-1×VEGF), the most direct competitor to ImmuneOnco's IMM2510 in NSCLC; shares the same bispecific antibody modality, oncology focus, and China-listed biotech profile.
- Genor Biopharma: Hong Kong-listed Chinese biotech developing monoclonal and bispecific antibodies for oncology and autoimmune diseases; overlapping therapeutic area and pipeline modality (immuno-oncology biologics) and clinical-stage profile.
- Trillium Therapeutics (Gilead): Developer of magrolimab (CD47 monoclonal antibody), the most advanced Western CD47 program and the most direct mechanistic competitor to ImmuneOnco's IMM01 SIRPα-Fc fusion protein in hematologic malignancies.
Broad incumbents
- BeiGene, Ltd. Global commercial-stage oncology biotech with broad pipeline including hematology assets (e.g., BRUKINSA); comparable as a major China-headquartered immuno-oncology company with global commercial reach competing for similar patient populations.
Others
- Instil Bio, Inc. ImmuneOnco's primary global licensing partner (NASDAQ: TIL) holding ex-Greater China rights to IMM2510 and IMM27M; while not a direct product competitor, Instil Bio is integral to ImmuneOnco's commercial value capture and US clinical execution.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks2 records
Key highlights7 records
Customer concentration
宜明昂科生物医药技术(上海)有限公司 social profiles
Digital presence宜明昂科生物医药技术(上海)有限公司 financial estimates
Financial estimateRevenue estimate
Valuation estimate
宜明昂科生物医药技术(上海)有限公司 leadership team
Management profileNumber of profiles
Profiles9 records
宜明昂科生物医药技术(上海)有限公司 subsidiaries and ownership
Company hierarchySubsidiaries1 record
宜明昂科生物医药技术(上海)有限公司 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
宜明昂科生物医药技术(上海)有限公司 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 宜明昂科生物医药技术(上海)有限公司
What does 宜明昂科生物医药技术(上海)有限公司 do?
ImmuneOnco is a clinical-stage biopharmaceutical company developing immuno-oncology biologics, including bispecific antibodies built on its proprietary mAb-Trap platform, SIRPα-Fc fusion proteins, and recombinant protein therapeutics. Its pipeline of 10+ in-house originated drug candidates targets both innate and adaptive immune pathways for hematologic malignancies (e.g., CMML, follicular lymphoma), solid tumors (e.g., NSCLC, TNBC, HER2-positive cancers), and autoimmune diseases (e.g., SLE, IgG4-RD). The company currently monetizes selected assets (IMM2510 and IMM27M) through an ex-Greater China licensing deal with Instil Bio/Axion Bio valued at over US$2 billion and is building toward direct commercialization upon regulatory approvals.
Is 宜明昂科生物医药技术(上海)有限公司 a public or private company?
宜明昂科生物医药技术(上海)有限公司 is a public company. It is classified as public and is currently operating.
When was 宜明昂科生物医药技术(上海)有限公司 founded?
宜明昂科生物医药技术(上海)有限公司 was founded in 2015. It employs 11 to 50 people.
Where is 宜明昂科生物医药技术(上海)有限公司 based?
宜明昂科生物医药技术(上海)有限公司 is headquartered in Shanghai, China, in the Asia region.
How does 宜明昂科生物医药技术(上海)有限公司 make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are pharmaceutical Product Sales (Future).
Who are 宜明昂科生物医药技术(上海)有限公司's main competitors?
Direct peers on record are Junshi Biosciences, I-Mab Biopharma, Keymed Biosciences, CStone Pharmaceuticals, Innovent Biologics, Akeso, Inc., Genor Biopharma and Trillium Therapeutics (Gilead). BeiGene, Ltd. is listed as a broad incumbent. Instil Bio, Inc. is listed as an others.
Does 宜明昂科生物医药技术(上海)有限公司 have an API?
No public API is recorded for 宜明昂科生物医药技术(上海)有限公司.
What industry is 宜明昂科生物医药技术(上海)有限公司 in?
宜明昂科生物医药技术(上海)有限公司's product category is Immuno-Oncology Biologics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAD, Fusion Proteins & Fc-Engineered Biologics. Its NAICS code is 325414 and its SIC code is 2836.